Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 132 for “"Pancreatic Ductal Adenocarcinoma"”.
-
Regulation of CYP3A5 in Pancreatic Ductal Adenocarcinoma
… in high amounts in some cancers, including pancreatic ductal adenocarcinoma (PDAC). There have been several published studies regarding CYP3A5 regulators, but there is still much to be discovered concerning CYP3A5 regulation in cancer. To further understand the regulation of CYP3A5, a …
-
T Cell Immunosurveillance in Pancreatic Ductal Adenocarcinoma
ABSTRACT T CELL IMMUNOSURVEILLANCE IN PANCREATIC DUCTAL ADENOCARCINOMA Rebecca A. Evans Robert H. Vonderheide The prevailing theory of cancer immune surveillance, as understood from carcinogen-driven mouse models of highly mutated tumors, states that T cell-mediated immune pressure drives a …
-
Heparan Sulfate Proteoglycans in Pancreatic Ductal Adenocarcinoma (PDAC)
… (HSPG), Syndecan-1 (SDC1), as a key effector for pancreatic ductal adenocarcinoma (PDAC) progression whose surface expression is driven by KRAS*. By leveraging various PDAC models, we found that surface SDC1 expression was initially diminished upon mutant KRAS (KRAS*) signaling blockade but …
-
EPAC1 AS A THERAPEUTIC TARGET FOR PANCREATIC DUCTAL ADENOCARCINOMA
… of EPAC1 in promoting invasion and metastasis of pancreatic ductal adenocarcinoma (PDA) and immune regulation, through modulation of the activity of regulatory T-cells (Treg), a subset of T-cells that suppress the immune system and maintain immune tolerance. In three common PDA cell lines, AsPC-1, …
-
Investigating The Role of Cd109 In Pancreatic Ductal Adenocarcinoma
<p>Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in the US. We performed loss of function genomic screening on a cohort of four patient derived PDAC cell populations and our data shows a cell surface receptor CD109 to be a common vulnerability, the biologic role …
-
ZNF300 may influence the metastatic properties in pancreatic ductal adenocarcinoma
… gene expression to promote the tumorigenesis of pancreatic ductal adenocarcinoma (PDAC). Moreover, due to the overwhelming number of PDAC patients presented with metastasis at the time of diagnosis, it is necessary to better understand the process of metastasis. To understand the role of DNA …
-
Targeting Cyclin Dependent Kinases 4/6 Activity in Pancreatic Ductal Adenocarcinoma
Pages vi-xiii are incorrectly numbered as pages v-xii.
-
Learning from histopathology images: AI-driven biomarkers for pancreatic ductal adenocarcinoma
Contains fulltext : 332320.pdf (Publisher’s version ) (Closed access)
-
MRI Radiomics Modeling and Survival Prediction of Pancreatic Ductal Adenocarcinoma Patients
Pancreatic cancer is a particularly lethal and aggressive malignancy characterized by its late detection and 5-year survival of less than 10% for both men and women as of 2022. While many cancers come with symptoms of varying degrees, pancreatic cancer is largely asymptomatic until the disease …
-
Tracing clonal cell plasticity in the microenvironment of pancreatic ductal adenocarcinoma
… a vulnerability to cancer through acinar-to-ductal metaplasia and dedifferentiation by epithelial-mesenchymal transition, which contributes in largely unknown ways to metastasis in pancreatic cancer. As with most solid tumours, pancreatic ductal adenocarcinoma develops at the interface of …
-
MicroRNAs in Pancreatic Ductal Adenocarcinoma: New Approaches For Better Diagnosis And Therapy
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with less than an 8% 5-year survival rate, which has remained unchanged over the last 50 years. Early detection is particularly difficult due to the lack of disease-specific symptoms and reliable diagnostic …
-
Targeting Stromal-Mediated Resistance Mechanisms in Oncogenic KRAS-Driven Pancreatic Ductal Adenocarcinoma
<p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with oncogenic KRAS mutations driving both tumor initiation and maintenance. Despite recent breakthroughs in KRAS-targeted therapies, the rapid emergence of resistance mechanisms limits their clinical efficacy. …
-
Role of Methyltransferase Like-3 (Mettl3) In Pancreatic Ductal Adenocarcinoma (Pdac) Progression
<p>Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with about a 10% five-year survival rate. The grim prognostic situation of pancreatic cancer patients underlines the need to identify novel molecular targets. Recent studies have brought to attention, the need to therapeutically …
-
Aberrations of A Putative Tumor Suppressor Gene Sel1L In Pancreatic Ductal Adenocarcinoma
<p><strong>Introduction:</strong> Pancreatic cancer is the fourth leading cause of cancer-related death among males and females in the United States. <em>Sel-1-like </em>(<em>SEL1L</em>) is a putative tumor suppressor gene that is downregulated in a significant proportion of human pancreatic ductal …
-
Identifying genes that are required for the maintenance of pancreatic ductal adenocarcinoma
… are potentially important for the maintenance of Pancreatic Ductal Adenocarcinoma (PDAC). PDAC is the 4th leading cause for cancer-related deaths and exhibits a 5-year survival rate of less than 5%. Since PDAC is a Kras-driven cancer in that greater than 90% of PDACs contain a Kras mutation, we …
-
Investigating the Role of the Lysine-Specific Demethylase 4C in Pancreatic Ductal Adenocarcinoma
… involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC). Lysine demethylase 4C (KDM4C) is one of the chromatin modifying proteins frequently overexpressed across multiple solid cancers and is linked to chromatin instability, increased cell proliferation, and …
-
Host-intrinsic factors determine anti-tumor efficacy of exercise in pancreatic ductal adenocarcinoma
<p>Pancreatic Ductal Adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths with a low 5-year relative survival rate of approximately 13.3% for all stages combined. We have previously shown that exercise can improve quality of life and enhance functional capacity among patients …
-
Investigating the transcription factor landscape of the squamous subtype of pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, characterised by late diagnosis and early onset of metastases, and has a dismal 5-year survival of only 8\%. Based on gene expression profiles PDAC can be stratified into two distinct molecular subtypes: classical and …
-
Dissecting the impact of SMAD4 loss and KRAS mutations in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of ~10% that is set to make this disease the second leading cause of cancer-related deaths by 2040. Poor survival rates for PDAC are a consequence of late-stage diagnosis due to non-specific early-stage symptoms, and largely …
Page 1 of 7